THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Thursday, September 10, 2026
Incheon, South Korea: As the global biopharmaceutical industry advances toward more complex therapies and stricter quality expectations, maintaining robust aseptic processing capabilities has become a critical priority for manufacturers. The PDA Aseptic Processing of Biopharmaceuticals Conference 2026 will bring together regulatory experts, manufacturing leaders, and sterility assurance professionals on November 3–4, 2026, at the Sheraton Grand Incheon Hotel in South Korea to discuss emerging challenges and innovations shaping sterile manufacturing.
Organized by PDA Asia Pacific, the conference will focus on key areas influencing modern aseptic operations, including EU GMP Annex 1 implementation, contamination control strategies, inspection readiness, fill-finish technologies, microbiological risk management, primary packaging, and process validation. As manufacturers continue adapting to evolving regulatory expectations, the event aims to provide practical insights into building reliable and resilient aseptic manufacturing systems.
The conference will be co-chaired by DeokSeok Oh, President of the PDA Korea Chapter and Corporate Account Director at Ecolab, and Christian Scheuermann of Charles River Laboratories. PDA President and CEO Craig Elliott will also participate in the event, reflecting the conference’s importance as a global forum for advancing pharmaceutical manufacturing practices.
A key focus of the program will be the transition from compliance-driven approaches toward integrated quality systems that support long-term sterility assurance. Industry experts will discuss how manufacturers can strengthen contamination control frameworks, improve inspection preparedness, and manage risks across the entire aseptic processing lifecycle.
The event will feature perspectives from leading pharmaceutical and biotechnology organizations, including GC Biopharma, Lotte Biologics, and Samsung Biologics. Sessions will address areas such as visual inspection, quality culture, data integrity, process validation, and contamination control practices within advanced manufacturing environments.
Global regulatory specialists will also contribute insights into inspection expectations and international compliance requirements. Experts from organizations including ELIQUENT Life Sciences and Cytiva will discuss regulatory readiness, Annex 1 implementation, and approaches for aligning manufacturing operations with evolving global standards.
Beyond conference sessions, attendees will have the opportunity to participate in a pre-conference site visit to Daewoong Pharmaceutical’s Nabota Plant and Daewoong Bio’s Bio-Center on November 2, offering firsthand exposure to advanced biopharmaceutical manufacturing environments. The program will also connect with the PDA Contamination Control Strategy (CCS) Workshop 2026, scheduled for November 5, allowing participants to further explore practical contamination control approaches.
As biopharmaceutical production continues to expand across Asia and global markets, events focused on aseptic processing provide valuable platforms for knowledge exchange and collaboration. The PDA Aseptic Processing of Biopharmaceuticals Conference 2026 will support industry professionals in strengthening manufacturing excellence, improving quality systems, and preparing for the next generation of sterile drug production.
PharmaTech Outlook highlights initiatives that contribute to pharmaceutical innovation, manufacturing advancement, and regulatory excellence. Through coverage of industry-focused conferences such as this, the publication continues to showcase developments influencing the future of biopharmaceutical operations worldwide.
More in News